Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK129 Monotherapy or with AK117 in R/R cHL
NCT06642792Phase 2Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Jan 2025
- Primary completion
- Nov 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of AK129 in classic Hodgkin lymphoma (cHL), sponsored by Akeso, Inc.. Started Jan 2025; status: recruiting.
02
Drugs
AK129
03
Conditions
classic Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT06642792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06642792.